

Special Issue

Nanotechnology in Ovarian Cancer: Diagnosis and Treatment

Message from the Guest Editor

Ovarian cancer is frequently diagnosed at an advanced stage, posing challenges due to limited efficacious treatment options. Nanotechnology presents groundbreaking avenues to enhance early detection, precision drug delivery, and customized therapeutic interventions for individuals affected by ovarian cancer. In this Special Issue, we seek to publish cutting-edge research highlighting the latest advancements in the following areas:

Targeted Drug Delivery Approach Hyperthermia Therapy Nanoparticle-based Biomarker Detection Nanoparticle-based Biosensors In this Special Issue, we invite contributions that showcase the forefront of research in these areas, shedding light on the potential transformative impact of nanotechnology in the diagnosis and treatment of ovarian cancer.

Guest Editor

Dr. Shailendra Kumar Dhar Dwivedi
Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma, OK 73104, USA

Deadline for manuscript submissions

closed (25 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/193950

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)